Proto Labs IncPRLB
Proto Labs Inc Income Taxes Disclosure
Income Taxes
The Company is subject to income tax in multiple jurisdictions and the use of estimates is required to determine the provision for income taxes. For the years ended December 31, 2025, 2024 and 2023, the Company recorded an income tax provision of $9.8 million, $8.1 million and $10.7 million, respectively. The effective income tax rate for the years ended December 31, 2025, 2024 and 2023 was 31.6 percent, 32.7 percent and 38.4 percent, respectively.
The effective tax rate decreased by 1.1 percent for the year ended December 31, 2025 when compared to 2024, primarily due to a decrease in losses in foreign operations that are not eligible for tax benefits on account of valuation allowances, as well as a decrease in tax expense from the vesting of restricted stock and the exercise of stock options, partially offset by 2024 including a one-time reduction in deferred tax liabilities from being revalued at a lower state tax rate, that did not repeat in 2025.
The provision for income taxes is based on income before income taxes reported for financial statement purposes. The components of income before income taxes are as follows:
| Year Ended December 31, | |||||||||||||||||
| (in thousands) | 2025 | 2024 | 2023 | ||||||||||||||
| Domestic | $ | 47,066 | $ | 39,386 | $ | 38,099 | |||||||||||
| Foreign | (16,004) | (14,714) | (10,147) | ||||||||||||||
| Total | $ | 31,062 | $ | 24,672 | $ | 27,952 | |||||||||||
Significant components of the provision for income taxes for the following periods are as follows:
| Year Ended December 31, | |||||||||||||||||
| (in thousands) | 2025 | 2024 | 2023 | ||||||||||||||
| Current: | |||||||||||||||||
| Federal | $ | 6,031 | $ | 11,970 | $ | 15,717 | |||||||||||
| State | 912 | 1,451 | 2,418 | ||||||||||||||
| Foreign | — | (165) | 34 | ||||||||||||||
| Deferred | |||||||||||||||||
| Federal | 4,161 | (4,606) | (8,202) | ||||||||||||||
| State | (231) | (1,291) | (385) | ||||||||||||||
| Foreign | (2,974) | (3,736) | 1,379 | ||||||||||||||
| Valuation Allowance | 1,922 | 4,456 | (229) | ||||||||||||||
| Total | $ | 9,821 | $ | 8,079 | $ | 10,732 | |||||||||||
A reconciliation of the federal statutory income tax rate to the effective tax rate for fiscal year 2025, after the prospective adoption of ASU 2023-09 is as follows:
| Year Ended December 31, | ||||||||||||||
| 2025 | ||||||||||||||
| Amount | Percent | |||||||||||||
| Federal tax statutory rate | $ | 6,524 | 21.0 | % | ||||||||||
State tax (net of federal benefit)1 | 877 | 2.8 | ||||||||||||
| Foreign tax effects | ||||||||||||||
| Germany | ||||||||||||||
| Valuation allowance | 1,487 | 4.8 | ||||||||||||
| Foreign tax rate differential | (384) | (1.2) | ||||||||||||
| Netherlands | ||||||||||||||
| Valuation allowance | 1,379 | 4.4 | ||||||||||||
| Other | (256) | (0.8) | ||||||||||||
| Other foreign jurisdictions | (46) | (0.1) | ||||||||||||
| Tax credits | ||||||||||||||
| Research and development credit | (547) | (1.8) | ||||||||||||
| Tax reserves | (282) | (0.9) | ||||||||||||
| Nontaxable or nondeductible items | ||||||||||||||
| Share based compensation | 304 | 1.0 | ||||||||||||
| Executive compensation | 733 | 2.4 | ||||||||||||
| Other adjustments | 32 | — | ||||||||||||
| Total | $ | 9,821 | 31.6 | % | ||||||||||
1 During the year ended December 31, 2025, the tax effect in this category was primarily driven by state taxes in California (greater than 50 percent).
A reconciliation of the federal statutory income tax rate to the effective tax rate for fiscal years 2024 and 2023 prior to the adoption of ASU 2023-09 is as follows:
| Year Ended December 31, | |||||||||||
| 2024 | 2023 | ||||||||||
| Federal tax statutory rate | 21.0 | % | 21.0 | % | |||||||
| State tax (net of federal benefit) | 2.5 | 3.5 | |||||||||
| Share based compensation | 4.7 | 6.0 | |||||||||
| Valuation allowance against deferred tax assets | 16.6 | (2.4) | |||||||||
| Research and development credit | (4.1) | (3.8) | |||||||||
| Foreign rate differential | (3.7) | (1.6) | |||||||||
| Tax reserves | (0.2) | 1.9 | |||||||||
| Provision to return difference | (0.2) | (0.2) | |||||||||
| Unrealized foreign exchange losses | — | 2.9 | |||||||||
| Revaluation of deferred tax liability | (3.2) | 1.1 | |||||||||
| Closure of Japan branch net operating loss reversal | — | 11.1 | |||||||||
| Miscellaneous | (0.7) | (1.1) | |||||||||
| Total | 32.7 | % | 38.4 | % | |||||||
Significant components of deferred tax assets and liabilities are as follows:
| December 31, | |||||||||||
| (in thousands) | 2025 | 2024 | |||||||||
| Deferred tax assets: | |||||||||||
| Accrued expenses | $ | 3,339 | $ | 1,658 | |||||||
| Section 174 expenses | 7,191 | 15,058 | |||||||||
| Leases | 797 | 897 | |||||||||
| Stock options and other equity | 3,494 | 5,402 | |||||||||
| Inventories | 341 | 216 | |||||||||
| Research and development credit | 2,937 | 2,760 | |||||||||
| Other assets | 1,455 | 1,212 | |||||||||
| Net operating loss | 23,037 | 19,738 | |||||||||
| Less valuation allowance | (22,296) | (21,782) | |||||||||
| Total deferred tax assets | 20,295 | 25,159 | |||||||||
| Deferred tax liabilities: | |||||||||||
| Depreciation | (18,030) | (21,505) | |||||||||
| Goodwill | (16,495) | (14,449) | |||||||||
| Intangible assets | (1,571) | (1,873) | |||||||||
| Leases | (797) | (897) | |||||||||
| Total deferred tax liabilities | (36,893) | (38,724) | |||||||||
| Net deferred tax liability | $ | (16,598) | $ | (13,565) | |||||||
The Company has recorded no U.S. deferred taxes related to the undistributed earnings of its non-U.S. subsidiaries as of December 31, 2025. Such amounts are intended to be reinvested outside of the United States indefinitely, and it is not practicable to estimate the amount of additional tax that might be payable on the foreign earnings. As of December 31, 2025, the Company had no accumulated undistributed earnings in non-U.S. subsidiaries.
As of December 31, 2025, the Company had estimated net operating loss carry forwards of $23.0 million for tax purposes. The net operating losses relate to operations in the United Kingdom, Germany and Netherlands. The United Kingdom net operating losses may be carried forward without any time limitations, but are limited to £5 million, plus 50 percent of taxable income exceeding £5 million. Germany net operating losses may be carried forward without any time limitations but are limited to €1 million, plus 60 percent of taxable income exceeding €1 million. Netherlands net operating losses may be carried forward without any time limitations, but are limited to €1 million, plus 50 percent of taxable income exceeding €1 million.
As of December 31, 2025, the Company had an estimated Minnesota R&D credit carry forward of $3.7 million available to reduce future income taxes. The Minnesota R&D credit can be carried forward 15 years, with expiration beginning in 2029.
The Company establishes valuation allowances for deferred tax assets when, after consideration of all positive and negative evidence, it is considered "more-likely-than-not" that a portion of the deferred tax assets will not be realized. The Company's valuation allowances of $22.3 million and $21.8 million at December 31, 2025 and 2024, respectively, reduce the carrying value of deferred tax assets associated with certain net operating loss carry forwards and other assets with insufficient positive evidence for recognition. The increase in the valuation allowance is primarily attributable to additional net operating losses generated in 2025.
The Company files a U.S. federal income tax return and income tax returns in various states and foreign jurisdictions. With a few exceptions, the Company is no longer subject to U.S. federal, state, or foreign income tax examinations by tax authorities for years before 2021.
The Company has liabilities related to unrecognized tax benefits totaling $3.1 million and $3.4 million at December 31, 2025 and 2024, respectively, that if recognized would result in a reduction of the Company’s effective tax rate. The liabilities are classified as other long-term liabilities in the accompanying consolidated balance sheets. The Company recognizes interest and penalties related to income tax matters in income tax expense and reports the liability in current or long-term income taxes payable as appropriate.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
| Year Ended December 31, | ||||||||||||||
| 2025 | 2024 | |||||||||||||
| Balance at beginning of period | $ | 3,370 | $ | 3,616 | ||||||||||
| Additions for tax positions of current year | 290 | 533 | ||||||||||||
| Additions for tax positions of prior years | 20 | — | ||||||||||||
| Decrease related to the expiration of statutes of limitations | (623) | (395) | ||||||||||||
| Reduction for tax positions of prior years | — | (384) | ||||||||||||
| Balance at period end | $ | 3,057 | $ | 3,370 | ||||||||||
A reconciliation of cash taxes paid (net of refunds received). All jurisdictions in which cash taxes paid (net of refunds received) were equal to or greater than five percent of total income taxes paid are included below, after the prospective adoption of ASU 2023-09 is as follows:
| Year Ended December 31, | |||||||||||
| 2025 | |||||||||||
| Federal | $ | 5,750 | |||||||||
| State: | |||||||||||
| California | 675 | ||||||||||
| All states representing less than five percent of total | 303 | ||||||||||
| Total State | 978 | ||||||||||
| Foreign | 16 | ||||||||||
| Total | $ | 6,744 | |||||||||
On July 4, 2025, the U.S. enacted H.R. 1 "A bill to provide for reconciliation pursuant to Title II of H. Con. Res. 14", commonly referred to as the One Big Beautiful Bill Act. As a result of the enactment of H.R. 1, the impact to the deferred tax liability and the income tax payable related to the provisions for 100% bonus depreciation for assets placed in service after January 19, 2025 and full expensing of domestic research and experimental expenditures is reflected in our results for year ended December 31, 2025. We do not expect any material change to our ongoing tax rate as a result of this legislation. We continue to evaluate the impacts the new legislation may have on the Company's financial statements.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 20, 2026 | Showing above |
| 2024 | Feb 21, 2025 | |
| 2023 | Feb 16, 2024 | |
| 2022 | Feb 21, 2023 | |
| 2021 | Feb 18, 2022 | |
| 2020 | Feb 19, 2021 | |
| 2019 | Feb 26, 2020 | |
| 2018 | Feb 22, 2019 | |
| 2017 | Feb 23, 2018 | |
| 2016 | Feb 22, 2017 | |
| 2015 | Feb 26, 2016 | |
About Income Taxes Disclosures
The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.
Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.